2026 Volume: 01 Issue: 06 ISSN 1671-2838 Page No: 27-38

Pharmaceutical Care and Research

https://pcrjournal.com

Review Article

Volume: 01 Issue: 06

# TRANSDERMAL DRUG DELIVERY SYSTEMS: INNOVATIONS, CHALLENGES, AND OPPORTUNITIES

**K.C. Praveen Kumar*[1], Dr. V. Kalvimoorthi[2], L. Gopi[3], Dr. M. Rajasekaran[4]**

[1]M. Pharm First Year, [2] Professor Cum HOD Department of Pharmaceutics, [3]Assistant Professor Department of Pharmaceutics, [4] Professor Cum HOD Department of Pharmaceutical Chemistry. Aadhi Bhagawan College of Pharmacy, Rantham, Thiruvannmalai, Tamilnadu.

**Article Received: 22 July 2026**
**Article Revised: 11 August 2026**
**Published on: 01 September 2026**

***Corresponding Author: K.C. Praveen Kumar**
M. Pharm First Year, Aadhi Bhagawan College of Pharmacy, Rantham, Thiruvannmalai, Tamilnadu.

DOI: https://doi-doi.org/101555/ijpcr.6663

## ABSTRACT

Transdermal drug delivery systems (TDDS) offer a patient-friendly alternative to conventional routes by avoiding first-pass metabolism, enabling controlled release, and enhancing adherence. Advances such as microneedle technology, nanocarrier-based formulations, and smart wearable patches have broadened TDDS applications from small molecules to complex biologics and vaccines. Nevertheless, limitations including skin barrier variability, formulation challenges, and regulatory concerns continue to hinder widespread clinical adoption. This review discusses recent innovations, key challenges, and emerging opportunities in TDDS, with emphasis on their role in chronic disease therapy, vaccination strategies, and personalized medicine.

**KEYWORDS:** TDDS, Polymers, Transdermal.

## 1. INTRODUCTION

Drug delivery systems are fundamental to modern medicine, as they influence not only how effective a drug is but also how well patients adhere to treatment and the overall success of therapy. Oral administration often suffers from low bioavailability because of first-pass hepatic metabolism. Injectables are invasive and uncomfortable, often reducing patient compliance. To address these drawbacks, transdermal drug delivery systems were developed, providing a painless, controlled, and patient-friendly alternative for administering medications. The first transdermal patch, introduced in 1979 for scopolamine, marked a turning point in this field. Since then, transdermal technology has advanced considerably, with current research focusing on broadening the types of drugs that can be delivered through the skin and enhancing the effectiveness of these systems.

Transdermal drug delivery systems (TDDS) are pharmaceutical formulations that deliver drugs through the intact skin into the systemic circulation. Since the approval of the first transdermal patch (scopolamine) in 1979, TDDS have become an important alternative to oral and parenteral drug administration. The skin serves as an effective protective barrier against environmental hazards while also regulating temperature and fluid balance. The outermost layer, the stratum corneum, presents the greatest obstacle to drug penetration. Consequently, only drugs with favorable physicochemical properties, such as low molecular weight, balanced lipophilicity, and high potency, are suitable for passive transdermal delivery. Technological advancements have expanded TDDS beyond traditional patches, enabling the delivery of peptides, proteins, vaccines, insulin, and biologics through novel enhancement techniques.




**Fig: 1 Human Skin.**

This review article provides a concise overview of the evolution of TDDS, exploring the biological barriers of skin permeation, current formulation strategies, and the emerging technologies shaping the future of transdermal therapeutics.

### 1.1 Skin Barrier and Mechanisms of Drug Transport

The skin, particularly the stratum corneum, serves as a formidable barrier to drug penetration. This outermost layer comprises keratinized cells embedded in a lipid matrix, which restricts the passage of hydrophilic and high-molecular-weight compounds. Drugs can traverse the skin through three primary pathways: transcellular, intercellular, and appendageal routes, although the latter contributes minimally under normal conditions. Passive diffusion, governed by Fick's law, is effective mainly for molecules with a molecular weight below 500 Da and moderate lipophilicity. These physicochemical constraints limit the range of drugs suitable for conventional transdermal delivery, thereby necessitating advanced enhancement technologies. A comprehensive understanding of skin physiology and its variability across individuals remains fundamental to the rational design of transdermal drug delivery systems.




**Fig: 2 Skin Barrier.**

The outermost layer of human skin, the stratum corneum (SC), is structured as a multilamellar lipid matrix embedded with protein rich coeneocytes. These cells reinforce the membrane's structural integrity while substantially increasing its internal tortiosity. Because of this lipophilic nature and highly winding diffusion pathway,the SC consistently acts as the primary rate limiting barrier against systemic drug absorption. To bypass this barrier, therapeutics agents are formulated as either solutions or suspensions, ranging in design complexity from simple topical gels and ointment to sophisticated, multilayered transdermal patches.

### 1.2 Structure of the Skin

The skin consists of three primary layers:

**A. Epidermis**

- Outermost protective layer
- Contains the stratum corneum
- Major barrier to drug penetration

**B. Dermis**

- Rich in blood vessels
- Contains hair follicles and sweat glands
- Responsible for systemic drug absorption

**C. Hypodermis**

- Fatty tissue
- Provides insulation and cushioning

### 1.3 Advantages of TDDS

- Avoids first-pass hepatic metabolism
- Maintains constant plasma drug concentration
- Sustained and controlled drug release
- Improved patient compliance
- Non-invasive administration
- Reduced gastrointestinal side effects
- Easy termination of therapy by removing the patch
- Suitable for chronic diseases

### 1.4 Limitations

- Only potent drugs are suitable
- Limited permeability of hydrophilic and large molecules
- Skin irritation and allergic reactions
- Variability due to skin thickness and hydration
- High manufacturing cost
- Limited dose capacity

### 1.5 Components of a Transdermal Patch

1. Backing membrane
2. Drug reservoir or matrix
3. Rate-controlling membrane (in reservoir systems)
4. Adhesive layer
5. Release liner
6. Penetration enhancer (optional)

### 1.6 Types of Transdermal Drug Delivery Systems

**A. Reservoir System**

- Drug enclosed in a reservoir
- Controlled by a membrane

**B. Matrix System**

- Drug dispersed within polymer matrix

**C. Drug-in-Adhesive System**

- Drug incorporated into adhesive layer

**D. Micro-reservoir System**

- Combination of reservoir and matrix systems

### 1.7 Ideal Characteristics of Drugs for TDDS

- Molecular weight <500 Da

- Daily dose <20 mg
- Moderate lipophilicity (Log P 1–3)
- Short biological half-life
- High potency
- Non-irritating
- Stable in skin environment

**1.8 Innovations In TDDS**

**1.8.1 Microneedle Technology**

Microneedles create microscopic channels in the skin without reaching pain receptors.

**Types**

- Solid microneedles
- Hollow microneedles
- Coated microneedles
- Dissolving microneedles
- Hydrogel-forming microneedles

**Applications**

- Insulin delivery
- Vaccines
- Peptides
- Cancer therapy

**1.8.2 Nanotechnology**

Nanocarriers improve drug solubility and penetration.

**Examples**

- Liposomes
- Niosomes
- Ethosomes
- Transfersomes
- Solid lipid nanoparticles
- Nanostructured lipid carriers
- Polymeric nanoparticles

**Advantages**

- Enhanced bioavailability
- Controlled release
- Targeted delivery

- Reduced toxicity

### 1.8.3 Iontophoresis

Uses low electrical current to enhance drug transport.

**Applications**

- Lidocaine
- Fentanyl
- Dexamethasone

**Advantages**

- Controlled delivery
- Rapid onset
- Improved permeation

### 1.8.4 Sonophoresis

Uses ultrasound waves to temporarily disrupt the skin barrier.

**Applications**

- Anti-inflammatory drugs
- Local anesthetics
- Insulin

### 1.8.5 Electroporation

Applies short electrical pulses to create temporary pores.

**Useful for**

- DNA vaccines
- Peptides
- Proteins

### 1.8.6 Thermal Ablation

Creates microscopic channels using controlled heat.

**Methods**

- Radiofrequency
- Laser
- Heated microarrays

### 1.8.7 Smart Transdermal Patches:

Advanced wearable devices integrated with:

- Biosensors
- Bluetooth
- Artificial intelligence
- Mobile applications

**Applications**

- Diabetes management
- Cardiovascular disease monitoring
- Personalized medicine

### 1.9 Clinical Applications

TDDS have found applications in a wide range of therapeutic areas. In chronic disease management, patches delivering hormones, analgesics, and cardiovascular drugs have improved patient adherence by providing steady plasma concentrations. Microneedle patches are being explored for vaccination, offering painless and self-administered alternatives to traditional injections. This approach is particularly valuable in resource-limited settings where cold-chain logistics are challenging. Oncology is another emerging area, with localized delivery of chemotherapeutics via TDDS reducing systemic toxicity. Dermatological conditions such as psoriasis and eczema also benefit from targeted transdermal therapies, which provide localized treatment with minimal systemic exposure.

### 1.10 Challenges In TDDS

Despite significant progress, several challenges hinder the widespread adoption of TDDS. Inter-individual variability in skin barrier properties—arising from age, ethnicity, or disease—complicates dose predictability. Formulation constraints further limit the range of drugs suitable for transdermal delivery, as only molecules with favourable physicochemical characteristics are effective. Device reliability, including patch adhesion and microneedle insertion consistency, directly influences therapeutic outcomes. Manufacturing and scalability present additional hurdles, since producing microneedles and smart patches at industrial scale while maintaining sterility and quality is complex. Finally, regulatory pathways for combination products that integrate drugs, devices, and software are stringent, necessitating extensive safety, efficacy, and performance data prior to approval.

## 2. INNOVATIONS IN TDDS

### 2.1 Micro-needle Technologies

Microneedles represent one of the most significant innovations in TDDS. These miniature projections painlessly pierce the stratum corneum, creating microchannels that allow drugs to bypass the barrier and reach deeper skin layers. Several designs have been developed, including solid, coated, dissolving, hollow, and hydrogel microneedles, each offering distinct advantages. For example, dissolving microneedles composed of biocompatible polymers can deliver vaccines or peptides while eliminating concerns about needle disposal. Clinical studies have demonstrated their potential in delivering insulin, vaccines, and cancer therapeutics. Despite their promise, challenges such as mechanical strength, dose loading capacity, and large-scale manufacturing remain key hurdles to widespread clinical adoption.




**Fig: 2 Micro-needle Technologies.**

### 2.2 Nanocarrier-Based Systems

Nanocarriers such as liposomes, solid lipid nanoparticles, and polymeric nanoparticles have been extensively studied to enhance transdermal drug delivery. These carriers improve drug solubility, stability, and penetration through the skin by interacting with lipid components of the stratum corneum. For instance, insulin-loaded nanoparticles have demonstrated superior absorption compared to conventional formulations. Nanocarriers also protect sensitive molecules such as peptides and nucleic acids from enzymatic degradation, making them attractive for biologics delivery. Despite these promising attributes, challenges including reproducibility of particle size, long-term storage stability, and regulatory approval remain significant barriers to their widespread clinical adoption.

### 2.3 Energy-Assisted Systems

Energy-assisted methods such as iontophoresis, sonophoresis, and electroporation have been developed to enhance drug permeation. Iontophoresis uses a mild electrical current to drive charged molecules across the skin, offering controlled and on-demand dosing. Sonophoresis employs ultrasound waves to disrupt lipid packing in the stratum corneum, thereby increasing permeability. Electroporation involves applying short electrical pulses to create transient pores in the skin. These techniques have shown promise in delivering macromolecules and hydrophilic drugs, but device complexity, cost, and patient tolerance remain limiting factors.

### 2.4 Smart and Connected Patches

Recent advances have led to the development of smart patches that integrate biosensors with drug delivery systems. These patches can monitor physiological parameters such as glucose levels and release drugs in response to real-time data, enabling closed-loop therapy. Such systems hold great promise for personalized medicine, particularly in managing chronic conditions like diabetes. The integration of wireless communication allows data to be transmitted to healthcare providers, facilitating remote monitoring and improving patient outcomes. However, ensuring data security, device reliability, and user-friendly interfaces are critical for successful implementation.




**Fig: 3 Transdermal Patches.**

## 3. OPPORTUNITIES AND FUTURE DIRECTIONS

The future of TDDS lies in expanding their scope to biologics and vaccines, integrating with digital health platforms, and developing universal evaluation standards. Microneedle patches for vaccines could revolutionize immunization programs by enabling self-administration and reducing dependence on healthcare infrastructure. Smart patches with biosensors offer opportunities for personalized medicine, allowing dynamic dosing based on patient physiology. Advances in material science will enable stronger, biocompatible microneedles with higher payload capacity. Moreover, ensuring equity and accessibility in low-resource settings will broaden the global impact of TDDS, particularly in pandemic preparedness and chronic disease management.

Future research is focused on:

- Dissolving microneedle patches for vaccines and insulin.
- AI-assisted, feedback-controlled transdermal systems.
- Integration of biosensors with drug delivery patches.
- 3D-printed personalized transdermal patches.
- Stimuli-responsive systems activated by pH, temperature, or glucose levels.
- Improved nanocarriers for delivery of biologics, peptides, and nucleic acid-based therapeutics.

## 4. APPLICATIONS OF TDDS

**Table: 1 Application Of TDDS.**

| Therapeutic Area | Drugs |
|---|---|
| Pain management | Fentanyl, Diclofenac |
| Cardiovascular diseases | Nitroglycerin, Clonidine |
| Hormone replacement | Estradiol, Testosterone |
| Smoking cessation | Nicotine |
| Neurological disorders | Rivastigmine, Rotigotine |
| Motion sickness | Scopolamine |
| Contraception | Norelgestromin + Ethinyl estradiol |
| Parkinson's disease | Rotigotine |
| Alzheimer's disease | Rivastigmine |

## 5. EVALUATION OF TRANSDERMAL PATCHES:

### 5.1 Physicochemical Evaluation:

- Thickness
- Weight variation
- Folding endurance
- Moisture content
- Drug content uniformity

### 5.2 Mechanical Evaluation:

- Tensile strength
- Percentage elongation

- Adhesive strength

**5.3 In Vitro Evaluation:**

- Drug release studies
- Skin permeation studies
- Diffusion studies

**5.4 In Vivo Evaluation:**

- Pharmacokinetic studies
- Skin irritation studies
- Clinical efficacy

## 6. CONCLUSION

Transdermal drug delivery systems are evolving from simple patches to advanced, sensor-integrated platforms capable of delivering complex therapeutics. Innovations in microneedles, nanocarriers, and smart patches are expanding the therapeutic landscape, while challenges in skin variability, formulation, and regulation remain. With continued interdisciplinary research and collaboration between academia, industry, and regulatory bodies, TDDS hold immense promise for revolutionizing drug delivery in chronic disease management, vaccination, and personalized medicine.

## 7. REFERENCES

1. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci. 2001;14(2):101–114.
2. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.
3. Ita K. Transdermal Drug Delivery: Progress and Challenges. J Drug Deliv Sci Technol. 2014;24(3):245–250.
4. Benson HAE, Watkinson AC, editors. Transdermal and Topical Drug Delivery: Principles and Practice. Hoboken, NJ: John Wiley & Sons; 2012.
5. Guy RH, Hadgraft J, editors. Transdermal Drug Delivery. 2nd ed. New York: Marcel Dekker; 2003.
6. Williams AC. Transdermal and Topical Drug Delivery: From Theory to Clinical Practice. London: Pharmaceutical Press; 2003.
7. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: Current and future prospects. Drug Deliv. 2006;13(3):175–187.
8. Alexander A, Dwivedi S, Giri TK, Saraf S, Saraf S, Tripathi DK. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J Control Release. 2012;164(1):26–40.
9. Ita K. Transdermal Delivery of Drugs with Microneedles—Potential and Challenges. Pharmaceutics. 2015;7(3):90–105.

10. Prausnitz MR. Engineering Microneedle Patches for Vaccination and Drug Delivery. Annu Rev Chem Biomol Eng. 2017;8:177–200.
11. Donnelly RF, Singh TRR, Woolfson AD. Microneedle-Based Drug Delivery Systems: Microfabrication, Drug Delivery, and Safety. Drug Deliv. 2010;17(4):187–207.
12. Kalia YN, Guy RH. Modeling Transdermal Drug Release. Adv Drug Deliv Rev. 2001;48(2–3):159–172.
13. Hadgraft J. Skin, the final frontier. Int J Pharm. 2001;224(1–2):1–18.
14. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: Overcoming the skin's barrier function. Pharm Sci Technolo Today. 2000;3(9):318–326.
15. Escobar-Chávez JJ, Merino-Sanjuán V, López-Cervantes M, et al. The Tape-Stripping Technique as a Method for Drug Quantification in Skin. J Pharm Pharm Sci. 2008;11(1):104–130.
16. United States Pharmacopeia (USP) 47–National Formulary (NF) 42. Rockville, MD: United States Pharmacopeial Convention; 2024.
17. Indian Pharmacopoeia Commission. Indian Pharmacopoeia 2022. 9th ed. Ghaziabad, India: IPC; 2022.
18. European Medicines Agency (EMA). Guideline on Quality of Transdermal Patches. Amsterdam: EMA; 2014.
19. U.S. Food and Drug Administration (FDA). Transdermal and Topical Delivery Systems—Product Development and Quality Considerations. Silver Spring, MD: FDA; 2019.
20. World Health Organization (WHO). WHO Technical Report Series: Good Manufacturing Practices for Pharmaceutical Products. Geneva: WHO; Latest edition.
21. Ita K. Current Advances in Transdermal Drug Delivery Systems. Pharmaceutics. 2021.
22. Moffatt K, Wang Y, Singh TRR, Donnelly RF. Microneedles for Transdermal Drug Delivery: Recent Advances and Clinical Applications. Adv Drug Deliv Rev. 2023.
23. Chen X, Li G, et al. Emerging Technologies in Transdermal Drug Delivery Systems. Int J Pharm. 2024.
24. Patel D, Sharma V, et al. Nanotechnology-Based Transdermal Drug Delivery Systems: Current Status and Future Perspectives. Drug Deliv Transl Res. 2023.
25. Zhang Y, Liu J, et al. Smart Transdermal Drug Delivery Systems: Recent Advances and Clinical Translation. J Control Release. 2024.